14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
ONCY vs BGM: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Oncolytics Biotech, Inc. Common Shares (ONCY) captures the overall head-to-head institutional edge over BGM Group Ltd. Class A (BGM) on higher Unified Composite conviction (44.5/100 HOLD vs. 59.6/100 HOLD) after splitting the core matrix 4–6 (led by Valuation Multiples, Profitability & Quality), while BGM wins 3–2 across the 6-pillar growth and valuation breakdown. ONCY trades at $0.35 (45.5x Forward P/E, 0.0% operating margin) versus BGM at $8.00 (N/M Forward P/E, -23.4% operating margin).
Composite vs. Pillar Nuance: While BGM currently prints a higher short-term Unified Composite Score (59.6/100 HOLD vs. ONCY 44.5/100 HOLD), ONCY captures the overall institutional head-to-head verdict (4–6 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -23.4% operating margin) and revenue trajectory (+0.0% vs. +69.8% YoY).
Technical & Structure Timing Caution: ONCY is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.4); meanwhile BGM trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 53.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ONCY vs BGM. Trailing 12-month operating profitability (ONCY 0.0% vs BGM -23.4%) and valuation multiples (ONCY 45.5x vs BGM N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Drug Manufacturers - Specialty & Generic value chain with $108.6M market capitalization and -23.4% operating margin.
OpEx & R&D Reinvestment40.3% of Rev ($19M)
90D Engineering Disclosures0 Published
Investor FAQ ONCY vs BGM Key Questions & Quantitative Answers
As of Nov 20, 2026, Oncolytics Biotech, Inc. Common Shares (ONCY) captures the overall head-to-head institutional edge over BGM Group Ltd. Class A (BGM) on higher Unified Composite conviction (44.5/100 HOLD vs. 59.6/100 HOLD) after splitting the core matrix 4–6 (led by Valuation Multiples, Profitability & Quality), while BGM wins 3–2 across the 6-pillar growth and valuation breakdown. ONCY trades at $0.35 (45.5x Forward P/E, 0.0% operating margin) versus BGM at $8.00 (N/M Forward P/E, -23.4% operating margin). Composite vs. Pillar Nuance: While BGM currently prints a higher short-term Unified Composite Score (59.6/100 HOLD vs. ONCY 44.5/100 HOLD), ONCY captures the overall institutional head-to-head verdict (4–6 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -23.4% operating margin) and revenue trajectory (+0.0% vs. +69.8% YoY). Technical & Structure Timing Caution: ONCY is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.4); meanwhile BGM trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 53.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
BGM leads the Growth & Scale pillar: ONCY posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with BGM at +69.8% YoY revenue growth and +0.0% YoY earnings growth on $48M TTM revenue (16.9% gross margin, -23.4% operating margin). On trailing 12-month operating scale, ONCY generates N/A in USD-normalized revenue versus $48M for BGM. In operating R&D and SG&A reinvestment, ONCY deploys N/A (0 90-day corporate R&D disclosures) versus 40.3% of Rev ($19M) (0 disclosures) for BGM.
ONCY screens cheaper on headline valuation multiples. ONCY trades at 45.5x Forward P/E, 45.5x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas BGM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 2.3x EV/Revenue (-19.3% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ONCY (-769.1% ROE) versus BGM (-7.4% ROE) capital efficiency.
In options market volatility and institutional positioning, ONCY carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.34β · 117% Vol realized risk). By comparison, BGM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (3.69β · 80% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.